A new 4-month regimen was described in a clinical trial published in 2021, which reported that a 4-month TB treatment regimen that included rifapentine 1200 mg orally once / day and moxifloxacin 400 mg orally once / day (1, 2) was noninferior to the standard 6-month regimen of rifampin, isoniazid, pyrazinamide, and ethambutol.